<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081479</url>
  </required_header>
  <id_info>
    <org_study_id>21-386</org_study_id>
    <nct_id>NCT05081479</nct_id>
  </id_info>
  <brief_title>A Study of N-Acetylcysteine (N-AC)in People Receiving CAR T-cell Therapy for Lymphoma</brief_title>
  <official_title>Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of N-AC when given in combination with&#xD;
      Yescarta to people with lymphoma. This study will test different doses of N-AC to find the&#xD;
      highest dose that causes few or mild side effects in participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">October 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 21, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of N-AC</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>This is a phase 1 dose escalation and expansion study to determine the maximum tolerated dose and recommended phase 2 dose of NAC given in conjunction with axicabtagene ciloleucel.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Participants with Lymphoma, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first dose escalation cohort in the study will be treated at 25% of that target dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Lymphoma, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The second cohort in the study will be treated at 50% of that target dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Lymphoma, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The third cohort in the study will be treated at 100% of that target dose level only if no DLTs are seen at lower doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>N-AC infusion will begin the day before CAR T cell infusion and continuously infused over 24-hours for 14 days or until time of discharge whichever is earlier. Interruptions of N-AC infusion for medical reasons are permissible. The dose for patients &lt;45kg will be adjusted to weight based dosing.</description>
    <arm_group_label>Participants with Lymphoma, Cohort 1</arm_group_label>
    <arm_group_label>Participants with Lymphoma, Cohort 2</arm_group_label>
    <arm_group_label>Participants with Lymphoma, Cohort 3</arm_group_label>
    <other_name>N-AC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be 18 years of age or older&#xD;
&#xD;
          -  Patients who will receive axicabtagene ciloleucel for treatment of lymphoma&#xD;
&#xD;
          -  Patients must have adequate end organ function to be eligible for this study as&#xD;
             defined by the following criteria:&#xD;
&#xD;
               -  ECOG performance status 0-2&#xD;
&#xD;
               -  Hematologic function with ANC ≥ 1000, Hgb ≥ 8, Plt ≥ 50k unless there is disease&#xD;
                  related hematologic toxicity&#xD;
&#xD;
               -  Renal function with CrCr ≥ 40 ml/min or Cr ≤ 1.5 x ULN&#xD;
&#xD;
               -  Hepatic function with ALT/AST ≤ 2.5 x ULN, TBili ≤ 1.5 x ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known allergy to N-AC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Connie Batlevi, MD, PhD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Connie Batlevi, MD, PhD, MS</last_name>
    <phone>646-608-3707</phone>
    <email>leec@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Santosha Vardhana, MD, PhD</last_name>
    <phone>646-888-3285</phone>
    <email>vardhans@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Connie Batlevi, MD, PhD, MS</last_name>
      <phone>646-608-3707</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>N-AC</keyword>
  <keyword>N-Acetylcysteine</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>CD19 CAR T-cell Therapy</keyword>
  <keyword>21-386</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

